{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:18:38Z","timestamp":1778084318961,"version":"3.51.4"},"reference-count":36,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["grant agreement No. 806968."],"award-info":[{"award-number":["grant agreement No. 806968."]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell\u2019Istruzione e del Merito","doi-asserted-by":"publisher","award":["PNRR M4C2I1.3 Heal Italia project PE00000019"],"award-info":[{"award-number":["PNRR M4C2I1.3 Heal Italia project PE00000019"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell\u2019Istruzione e del Merito","doi-asserted-by":"publisher","award":["PRIN 2015"],"award-info":[{"award-number":["PRIN 2015"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022- 12375970 Funded by the European Uni"],"award-info":[{"award-number":["PNRR-MAD-2022- 12375970 Funded by the European Uni"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca corrente 2025-2027"],"award-info":[{"award-number":["Ricerca corrente 2025-2027"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,3,29]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We comprehensively investigated whether serum acylcarnitine levels are associated with and predict the decline of glomerular filtration rate (GFR) in type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>Two cohorts of patients with type 2 diabetes were investigated: a subset of the aggregate Gargano Mortality Study (aGMS, n=575; 9 years of median follow-up; mean age=60.9\u00b19.8; mean diabetes duration=11.6\u00b19.3) as a discovery set from Italy. A sample from the Joslin Kidney Study (JKS, n=252; 10 years of median follow-up; mean age=57.8\u00b15.6; mean diabetes duration=14.2\u00b17.6) was used as an independent validation set with different environmental and ethnic background for some associated metabolites in the aGMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome<\/jats:title>\n                    <jats:p>\n                      estimated GFR (eGFR) change over time (mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven out of the 40 acylcarnitines (by the AbsoluteIDQTM p180 Kit, BIOCRATES) were significantly associated with the rate of eGFR decline after Bonferroni correction. All 11 molecules were internally validated (p&lt;0.05). Most of these associations survived the adjustment for several confounders, including age, sex, smoking habit, body mass index, glycated hemoglobin, disease duration, albumin excretion rate, triglycerides, low-density lipoprotein and statins treatment (p&lt;0.05). Tiglylcarnitine and methylglutarylcarnitine, but not tetradecenoylcarnitine and hexadecenoylcarnitine, were also associated with eGFR decline in the JKS (p&lt;0.05). Using multivariable least absolute shrinkage and selection operator regression analysis, methylglutarylcarnitine, hydroxyvalerylcarnitine, hexenoylcarnitine, decadienylcarnitine, dodecanedioylcarnitine, tetradecadienylcarnitine were independently associated with kidney function decline. The pairwise correlation among these ranged from \u22120.02 to 0.55. An acylcarnitine score comprising these six molecules improved discrimination (p&lt;0.01) and reclassification (p&lt;0.001) of two clinical prediction models of GFR decline in diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with type 2 diabetes, four short, three medium and four long-chain acylcarnitines are associated with the rate of kidney function decline. Adding the acylcarnitine score to clinical prediction models improves the identification of individuals who are at greater risk of progression to kidney failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-005748","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:45:13Z","timestamp":1778082313000},"page":"e005748","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Acylcarnitines and prediction of renal function decline in type 2 diabetes"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-127X","authenticated-orcid":false,"given":"Vincenzo","family":"Trischitta","sequence":"first","affiliation":[{"name":"Research Unit of Diabetes and Endocrine Diseases, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6660-5315","authenticated-orcid":false,"given":"Andrea","family":"Fontana","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-4572","authenticated-orcid":false,"given":"Hetal","family":"Shah","sequence":"additional","affiliation":[{"name":"Genetics and Epidemiology, Joslin Diabetes Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-1646","authenticated-orcid":false,"given":"Mario","family":"Mastroianno","sequence":"additional","affiliation":[{"name":"Scientific Direction, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-4715","authenticated-orcid":false,"given":"Cornelia","family":"Prehn","sequence":"additional","affiliation":[{"name":"Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum M\u00fcnchen Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt, Neuherberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"De Cosmo","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9259-0199","authenticated-orcid":false,"given":"Jerzy","family":"Adamski","sequence":"additional","affiliation":[{"name":"Institute of Experimental Genetics, Helmholtz Center Munich German Research Center for Environmental Health, Neuherberg, Germany"},{"name":"University of Ljubljana Faculty of Medicine, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7960-5947","authenticated-orcid":false,"given":"Massimiliano","family":"Copetti","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-4304","authenticated-orcid":false,"given":"Alessandro","family":"Doria","sequence":"additional","affiliation":[{"name":"Genetics and Epidemiology, Joslin Diabetes Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-8955","authenticated-orcid":false,"given":"Claudia","family":"Menzaghi","sequence":"additional","affiliation":[{"name":"Research Unit of Diabetes and Endocrine Diseases, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026050608450724000_14.3.e005748.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.08.026"},{"key":"2026050608450724000_14.3.e005748.2","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s00125-019-4948-4","article-title":"The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study","volume":"62","author":"Oshima","year":"2019","journal-title":"Diabetologia"},{"key":"2026050608450724000_14.3.e005748.3","doi-asserted-by":"crossref","first-page":"e1451","DOI":"10.1210\/clinem\/dgae551","article-title":"GFR Decline Predicts Total Mortality and Mediates the Effect of Tryptophan Metabolism on Death Risk in Type 2 Diabetes","volume":"110","author":"Lamacchia","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026050608450724000_14.3.e005748.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02539-2","article-title":"New strategies to improve clinical outcomes for diabetic kidney disease","volume":"20","author":"Forst","year":"2022","journal-title":"BMC Med"},{"key":"2026050608450724000_14.3.e005748.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.30"},{"key":"2026050608450724000_14.3.e005748.6","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1017340","article-title":"Applications of machine learning in metabolomics: Disease modeling and classification","volume":"13","author":"Galal","year":"2022","journal-title":"Front Genet"},{"key":"2026050608450724000_14.3.e005748.7","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.497"},{"key":"2026050608450724000_14.3.e005748.8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017030350"},{"key":"2026050608450724000_14.3.e005748.9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3345"},{"key":"2026050608450724000_14.3.e005748.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003422","article-title":"Circulating metabolites improve the prediction of renal impairment in patients with type 2 diabetes","volume":"11","author":"Trischitta","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026050608450724000_14.3.e005748.11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00125-024-06324-z","article-title":"Metabolomics profiling in multi-ancestral individuals with type 2 diabetes in Singapore identified metabolites associated with renal function decline","volume":"68","author":"Chen","year":"2025","journal-title":"Diabetologia"},{"key":"2026050608450724000_14.3.e005748.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33507-7","article-title":"Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations","volume":"8","author":"Barrios","year":"2018","journal-title":"Sci Rep"},{"key":"2026050608450724000_14.3.e005748.13","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa173","article-title":"Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes","volume":"105","author":"Tofte","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026050608450724000_14.3.e005748.14","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.kint.2019.07.025","article-title":"Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes","volume":"96","author":"Kammer","year":"2019","journal-title":"Kidney Int"},{"key":"2026050608450724000_14.3.e005748.15","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.jlr.2024.100552","article-title":"Association of plasma ceramide with decline in kidney function in patients with type 2 diabetes","volume":"65","author":"Gurung","year":"2024","journal-title":"J Lipid Res"},{"key":"2026050608450724000_14.3.e005748.16","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad166","article-title":"Exploration of Metabolomic Markers Associated With Declining Kidney Function in People With Type 2 Diabetes Mellitus","volume":"8","author":"Krasauskaite","year":"2023","journal-title":"J Endocr Soc"},{"key":"2026050608450724000_14.3.e005748.17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130317","article-title":"Increased lipogenesis and impaired \u03b2-oxidation predict type 2 diabetic kidney disease progression in American Indians","volume":"4","author":"Afshinnia","year":"2019","journal-title":"JCI Insight"},{"key":"2026050608450724000_14.3.e005748.18","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1210\/clinem\/dgae593","article-title":"Inflammation and Prediction of Death in Type 2 Diabetes. Evidence of an Intertwined Link With Tryptophan Metabolism","volume":"110","author":"Menzaghi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026050608450724000_14.3.e005748.19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.kint.2017.11.024","article-title":"Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development","volume":"93","author":"Nowak","year":"2018","journal-title":"Kidney Int"},{"key":"2026050608450724000_14.3.e005748.20","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0630"},{"key":"2026050608450724000_14.3.e005748.21","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2337\/dc21-1789","article-title":"Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies","volume":"45","author":"Shah","year":"2022","journal-title":"Diabetes Care"},{"key":"2026050608450724000_14.3.e005748.22","doi-asserted-by":"crossref","unstructured":"Steyerberg E . Clinical prediction models: a practical approach to development, validation, and updating. 2019.","DOI":"10.1007\/978-3-030-16399-0"},{"key":"2026050608450724000_14.3.e005748.23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1467-9868.2011.00771.x","article-title":"Regression Shrinkage and Selection via The Lasso: A Retrospective","volume":"73","author":"Tibshirani","year":"2011","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2026050608450724000_14.3.e005748.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0415-5"},{"key":"2026050608450724000_14.3.e005748.25","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1604"},{"key":"2026050608450724000_14.3.e005748.26","doi-asserted-by":"publisher","DOI":"10.2307\/2531595"},{"key":"2026050608450724000_14.3.e005748.27","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2929"},{"key":"2026050608450724000_14.3.e005748.28","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4085"},{"key":"2026050608450724000_14.3.e005748.29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052717","article-title":"The Role of l-Carnitine in Mitochondria, Prevention of Metabolic Inflexibility and Disease Initiation","volume":"23","author":"Virmani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026050608450724000_14.3.e005748.30","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0940"},{"key":"2026050608450724000_14.3.e005748.31","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07650717"},{"key":"2026050608450724000_14.3.e005748.32","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1369"},{"key":"2026050608450724000_14.3.e005748.33","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.121.000408"},{"key":"2026050608450724000_14.3.e005748.34","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261931"},{"key":"2026050608450724000_14.3.e005748.35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2147\/DMSO.S350233","article-title":"Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?","volume":"15","author":"Mu","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026050608450724000_14.3.e005748.36","doi-asserted-by":"crossref","first-page":"156257","DOI":"10.1016\/j.metabol.2025.156257","article-title":"Prediction models for the implementation of precision medicine in the real world. Some critical issues","volume":"170","author":"Menzaghi","year":"2025","journal-title":"Metab Clin Exp"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-005748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:45:24Z","timestamp":1778082324000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-005748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,6]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjdrc-2025-005748"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-005748","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}